来曲唑早期治疗持续性的副作用影响:EvAluate-TM前瞻性研究结果
EvAluate-TM非干预研究纳入3887例绝经后激素受体阳性早期乳腺癌患者,分析来曲唑治疗前30天内不良事件对治疗持续性的影响。12个月持续率>85%,14.6%患者停药,其中63.0%仅因副作用停药;肌肉骨骼症状、睡眠障碍和其他不良事件是影响持续性的主要因素,而更年期症状无显著关联。
要点
- 肌肉骨骼症状(HR 2.55)和睡眠障碍(HR 1.95)显著增加早期停药风险。
- 14.6%患者12个月内停药,其中63.0%仅因副作用停药。
- 更年期症状与治疗不持续无显著关联(HR 1.17)。
核心结论
- 来曲唑治疗中肌肉骨骼综合征和睡眠障碍等副作用导致相当比例早期乳腺癌患者在治疗第一年内停药。
研究设计与样本
- EvAluate-TM是一项非干预前瞻性研究,纳入3887例开始来曲唑治疗的绝经后激素受体阳性早期乳腺癌患者。
- 治疗依从性和持续性信息在第6个月和第12个月收集,持续性定义为从开始后30天至治疗结束的时间。
- 采用Cox回归分析前30天内肌肉骨骼综合征、更年期障碍、睡眠障碍和其他不良事件对持续性的影响。
主要发现
- 12个月持续率>85%,568例(14.6%)患者停药,其中358例(63.0%)仅因副作用停药。
- 影响持续性的主要不良事件为肌肉骨骼症状(HR 2.55;95%CI 1.90-3.42)、睡眠障碍(HR 1.95;95%CI 1.41-2.70)和其他不良事件(HR 2.03;95%CI 1.51-2.73)。
- 更年期障碍与治疗不持续无显著关联(HR 1.17;95%CI 0.74-1.84)。
临床怎么用
- 针对有早期停药风险的亚组,适应性的依从性管理项目可能有助于确保推荐的治疗时长。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endocrine treatment (ET) with an aromatase inhibitor (AI) is the treatment of choice in post-menopausal patients with hormone receptor-positive early breast cancer (EBC). However, adverse events (AEs) often lead to treatment discontinuation. This analysis aimed to identify side-effects that lead to patients failing to persist with letrozole treatment. PATIENTS AND METHODS: Post-menopausal hormone receptor-positive EBC patients starting ET with letrozole were enroled in EvAluate-TM, a non-interventional study. Information regarding treatment compliance and persistence was gathered in months 6 and 12. Persistence was defined as the time from 30 d after the start to the end of treatment. The influence on persistence of musculoskeletal syndrome, menopausal disorder, sleep disorder and other AEs within the first 30 d was analysed using Cox regression analyses. RESULTS: Among 3887 patients analysed, the persistence rate after 12 months was >85%. In all, 568 patients (14.6%) discontinued the treatment, 358 of whom (63.0%) did so only because of side-effects. The main AEs influencing persistence were musculoskeletal symptoms (hazard ratio [HR] 2.55; 95% confidence interval [CI], 1.90-3.42), sleep disorders (HR 1.95; 95% CI, 1.41-2.70) and other AEs (HR 2.03; 95% CI, 1.51-2.73). Menopausal disorder was not associated with non-persistence (HR 1.17; 95% CI, 0.74-1.84). CONCLUSIONS: These results suggest that side-effects of AIs such as musculoskeletal syndrome and sleep disorder lead to ET discontinuation within the first treatment year in significant numbers of EBC patients. Compliance programmes adapted for subgroups that are at risk for early non-persistence might help to ensure the recommended therapy duration. CLINICAL TRIALS NUMBER: CFEM345DDE19.
引用
- Nabieva N, Fehm T, Häberle L, et al. Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study. Eur J Cancer. 2018. PMID: 29679775. doi:10.1016/j.ejca.2018.03.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。